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Abstract: The properties of stem cells can be induced during the epithelial to mesenchymal transition (EMT). The
responsible molecular mechanisms, however, remain largely undefined. Here we report the identification of the
microRNA-146a (miR-146a) as a common target of Krüppel-like factor 8 (KLF8) and TGF-β, both of which are known
EMT-inducers. Upon KLF8 overexpression or TGF-β treatment, a significant portion of the MCF-10A cells gained stem
cell traits as demonstrated by an increased expression of CD44high/CD24low, activity of aldehyde dehydrogenase
(ALDH), mammosphere formation and chemoresistance. Along with this change, the expression of miR-146a was
highly upregulated in the cells. Importantly, we found that miR-146a was aberrantly co-overexpressed with KLF8 in
a panel of invasive human breast cancer cell lines. Ectopic expression of KLF8 failed to induce the stem cell traits
in the MCF-10A cells if the cells were pre-treated with miR-146a inhibitor, whereas overexpression of miR-146a
in the MCF-10A cells alone was sufficient to induce the stem cell traits. Co-staining and luciferase reporter analyses indicated that miR-146a targets the 3’-UTR of the Notch signaling inhibitor NUMB for translational inhibition.
Overexpression of KLF8 dramatically potentiated the tumorigenecity of MCF-10A cells expressing the H-Ras oncogene, which was accompanied by a loss of NUMB expression in the tumors. Taken together, this study identifies a
novel role and mechanism for KLF8 in inducing pro-tumorigenic mammary stem cells via miR-146a potentially by
activating Notch signaling. This mechanism could be exploited as a therapeutic target against drug resistance of
breast cancer.
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Introduction
EMT plays a key role in normal embryogenesis
and wound healing [1]. A large body of evidence
suggests a role of aberrantly activated EMT in
tumor initiation and malignant progression [1,
2]. Cancer stem cells (CSCs) are a rare subpopulation of cancer cells that are able to selfrenew, differentiate and are thought to be
responsible for tumor initiation, growth, invasion, metastasis, recurrence, and resistance to
various therapies [3]. Recent studies have
linked EMT to induction or maintenance of
mammary stem cells associated with malignant transformation [4, 5]. MicroRNAs (miRs), a
family of short non-coding regulatory RNAs targeting mRNA 3’-untranslated region (3’-UTR) to
regulate gene expression, have recently
emerged as critical regulators of tumor pro-

gression and CSCs and are thus tightly regulated in the cell [6, 7]. However, how miRs regulate
EMT-associated CSC properties remain in its
infancy of studies.
KLF8 is among a few master EMT-promoting
transcriptional factors [8, 9]. In addition to
repressing E-cadherin to promote EMT [9, 10],
KLF8 also targets other important genes such
as cyclin D1 [9, 11-14] and MMP9 [15] that are
associated with tumor progression of various
cancer types including breast cancer [8-10,
15-25]. KLF8 has also been reported to regulate the transcription of KLF4 [13] and Wnt signaling [26] both of which are important regulators of stem cells and cancer [27, 28]. Given
these important roles of KLF8 as a dual transcription factor [13-15, 29, 30], its expression
is tightly regulated in the cells at various levels
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including transcription [14, 16, 31, 32], posttranslational modifications [11-13, 33] and
subcellular localization [33, 34]. Unlike other
regulators of EMT such as Snail, TWIST and
ZEBs which target a consensus E-box(es) at
their target gene promoters [1], KLF8 represents a distinct family of transcription factors
(i.e., KLFs) and targets a consensus GT-box(es)
to regulate its target gene expression [8]. This
difference suggests that KLF8 may regulate a
distinct group of genes or miRs associated with
EMT or stem cells during cancer progression.
In this study, we sought to find out the first miRs
that are regulated by KLF8 and identified miR146a as one of primary target miRs of KLF8
that links mammary stem cell induction to
oncogenic transformation.
Material and methods
Cell culture, reagents and plasmid construction
MCF-10A, MCF-7, T47D, MDA-MB-231, Hs578T
and BT-549 cell lines [9, 17] and the MCF-10A
line that expresses inducible KLF8 (10A-iK8)
and the MDA-MB-231 line that expresses
inducible KLF8 short hairpin RNA (231-K8ikd)
[15, 35] were described previously. The overexpression or knockdown of KLF8 was induced by
doxycycline included in the culture medium.
The Cy3 dye-labeled negative control miR inhibitor and miR-146a inhibitor were purchased
from Dharmacon (Lafayette, CO, USA). Their
transfection was done using Oligofectamine
(Invitrogen, Grand Island, NY, USA). To construct
pIS1-NUMB-3’-UTR luciferase reporter, we
amplified the NUMB 3’-UTR fragment (nucleotides 3-1253) by RT-PCR and ligated it into pIS1
reporter vector (Addgene ID: 12179, Cambridge,
MA, USA) [36] between the AgeI and XbaI sites.
Primers used for the cloning were 5’-ATG CAC
CGG TAA TCA TTA TGG CTA TGT ATC TTG TC (forward) and 5’-ATG CTC TAG AAG ATG AGC TCT
CTT ATT GTT ATC C (reverse). To construct the
miR-146a-binding defective mutant reporter,
the miR-146a binding site in the 3’-UTR was
disabled by site-directed mutagenesis PCR
using the pIS1-NUMB-3’-UTR luciferase reporter as template and the primers of 5’-ata gac tac
aga tat taa gaa g (forward) and 5’-tct gta gtc tat
tta aaa tat tc (reverse). To construct pBabemCherry-miR-146a sponge, we cloned mCherry
into pBabe-puro vector [9] between the BamHI
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and EcoRI sites. We then cloned the annealed
oligonucleotides for miR-146a sponge into
pBabe-puro-mCherry vector between the EcoRI
and SalI sites. The sequences of the sponge oligos consisting of 4 tandem miR-146a binding
sites with 4-nucleotide spacers at the bulged
sites were 5’-AAT TCA ACC CAT GGA TGC AGT
TCT CAA GTA ACC CAT GGA TGC AGT TCT CAT
CAA ACC CAT GGA TGC AGT TCT CACT GAA CCC
ATG GAT GCA GTT CTC AA (sense) and 5’-CCG
GTT GAG AAC TGC ATC CAT GGG TTC AGT GAG
AAC TGC ATC CAT GGG TTT GAT GAG AAC TGC
ATC CAT GGG TTA CTT GAG AAC TGC ATC CAT
GGG TTG (antisense). Retroviruses derived
from the pBabe-puro-mCherry-miR-146a-sponge or pBabe-puro-mCherry vector were used to
infect the 10A-iK8 cells. The respective
10A-iK8-miR-146a-sponge cell line and 10AiK8-miR-sponge mock cell line were established by puromycin selection. To stably overexpress miR-146a, we transferred the pre-miR146a template from pcDNA3-miR-146a vector
(Addgene ID: 15092, Cambridge, MA, USA) [37]
between BamHI and SalI sites into pBabe-neo
vector (Addgene ID: 1767, Cambridge, MA, USA)
between BamH I and XhoI sites to form the
pBabe-neo-miR-146a retroviral vector. Viruses
derived from this vector or pBabe-neo control
vector were used to infect MCF-10A cells. The
respective MCF-10A-miR-146a and MCF-10AmiR-mock cell lines were established by G418
selection. 10A-iK8-V12 and 10A-iK8-GFP control cell lines were generated by retroviral infection using the retroviral vector MSCV H-Ras V12
IRES GFP (Addgene, Plasmid 18780, Cambridge, MA, USA) and control vector pMIG
(Addgene: Plasmid 9044, Cambridge, MA,
USA), respectively, followed by GFP-based
96-well plate cloning. A 3’-UTR-less human
NUMB-GFP fusion was used to replace the GFP
in the pMIG vector to generate 10A-iK8-NUMB
cell line similarly.
Fluorescence activated cell-sorting (FACS)
analysis
For quantification of cells expressing the human
breast stem cell marker proteins CD44 and
CD24, cells were trypsinized and washed with
PBS containing 2% of FBS. The cell surface
marker proteins were detected by incubating
the cells with anti-CD44-FITC (clone G44-26)
and anti-CD24-PE (clone ML5) antibodies (BD
Bioscience, Franklin Lakes, NJ, USA) in the
manufacturer-recommended dilutions at 4°C
for 30 minutes. After washing three times, anal-
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ysis was performed using a flow cytometer
(FACScalibur, BD Biosciences, Franklin Lakes,
NJ, USA). Ten thousand events were acquired
for each sample and analyzed with FlowJo
software.
ALDEFLUOR assay
The ALDEFLUOR kit (StemCell Technologies,
Vancouver, BC, Canada) was used to isolate the
aldehyde dehydrogenase (ALDH) enzymatic
activity-positive cell population according to
the manufacturer’s instruction. Briefly, cells
were detached with 0.25% trypsin/EDTA,
washed with PBS supplemented with 2% FBS
and suspended in ALDEFLUOR assay buffer
containing ALDH substrate (BAAA, 1 μmol/L for
1×106 cells) and incubated at 37°C for 40 minutes. As a negative control, an equivalent cell
aliquot was treated with 50 μmol/L of diethylaminobenzaldehyde (DEAB), a specific ALDH
inhibitor. The gates for FACS were established
using the ALDEFLUOR-stained cells treated
with DEAB to define the baseline fluorescence
of the cells (R1) and the ALDEFLUOR-positive
region (R2).
MicroRNA expression profiling analysis
The 10A-iK8 cells were grown under uninduced
(U) or induced (I) conditions for 7 days. The total
RNA was prepared from the cells using Trizol
(Invitrogen, Carlsbad, CA, USA). Forty μg of the
total RNA was used to isolate total miroRNA
using the small RNA isolation kit-RT²-qPCR
Grade miRNA Isolation Kit (MA-01, SABioscienc,
Valencia, CA, USA). Then, 100 ng of the small
RNA sample was used to synthesize the first
strand cDNAs for the microRNAs using RT2
miRNA first strand kit (MA-03, SABioscienc,
Valencia, CA, USA). The cDNAs were then used
as templates to screen the whole human
genome miRNA PCR array (MAH-100A,
SABioscienc, Valencia, CA, USA) using quantitative real-time reverse transcription-PCR (qRTPCR) for the profiling by following the manufacturer’s instruction. In some experiments, individual microRNAs were examined similarly to
determine their expression in MCF-10A cells
that were treated with TGF-β (2.5 ng/ml) for 7
days or in a panel of human breast cancer cell
lines.
Promoter reporter assays
Luciferase reporter assays were performed
essentially as described previously [9]. Briefly,
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HEK293 cells were co-transfected with the
wild-type or mutant pIS1-NUMB-3’-UTR luciferase reporter pIS1 and pBABE-neo-miR-146a or
pBABE-neo control vector along with the normalizing control vector pIS0 encoding Firefly
luciferase (Addgene ID: 12178, Cambridge, MA,
USA) [36]. After 36 hours, luciferase activity
was determined using the dual luciferase
reporter assay system (Promega, Fitchburg, WI,
USA) and 20/20n luminometer (Turner
BioSystems, Sunnyvale, CA, USA) according to
the manufacturers’ instructions.
Mammosphere formation assay
Mammosphere culture was performed as
described [38]. Cells (3000 to 104 per well)
were plated in the ultra-low adherent 6-well
plates and cultured in the MammoCultTM basal
medium with proliferation supplements
(STEMCELL Technologies, Vancouver, BC,
Canada) for 7-10 days prior to sphere counting
and photography. Mammospheres greater than
75 μm in diameter were counted as positive
spheres.
Co-staining of cellular miR-146a and NUMB
The fluorescent in situ hybridization coupled
with tyramide-signal amplification (FISH-TSA)
was performed as previously described [39].
Briefly, cells grown on glass coverslips were
fixed, permeabilized and prehybridized. Cells
were then hybridized with 20 μM of miR-146a
probes (EXIQON, Woburn, MA, USA) for overnight at 52°C, washed and blocked with blocking buffer. After incubated with 0.05 units/ml of
peroxidase-conjugated sheep anti-DIG antibody (Roche, Indianapolis, IN), cover slips were
further incubated with biotin-tyramide for TSA
in a TSA-PLUS system (Perkin-Elmer, Boston,
MA, USA) followed by incubation with SAFluorescein. After the FISH-TSA, the cellular
NUMB protein was stained with anti-NUMB
antibody (Cell Signaling, Danvers, MA, USA) and
Texas-red conjugated secondary antibody. Cell
imaging was processed and analyzed with a
fluorescent confocal microscope.
Western blotting (WB) and immunohistochemical (IHC) staining
WB and IHC staining were carried out as previously described [15, 23]. The antibodies used
in IHC include rabbit anti-human KLF8 antibody
[9] and rabbit anti-human NUMB monoclonal
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antibody (C29G1, Cell Signaling, Danvers, MA,
USA).
Mammary tumorigenecity in immunocompromised mice
Four to 5-week-old NOD/SCID mice (12 mice
per cell line. Taconic, Germantown, NY, USA)
were injected with the 10A-iK8, 10A-iK8-V12 or
10A-iK8-GFP cells (2 x 106 in 100 μl mixture of
PBS and Matrigel mix (1:1)) into the right hind
mammary fat pad. The mice were fed with the
Dox Diet (3888) (Bio Servs, Frenchtown, NJ,
USA) supplemented with doxycycline (200 mg/
kg) to induce the expression of KLF8 in the
tumor cells in vivo or with the Control Diet
(S4207) not containing doxycycline. Tumors
formed by the cells were monitored for 7
months before the tumors were photographed
and dissected. Tumor length (L) and width (W)
were measured using a Vernier caliper, and
mean tumor volume was calculated by the formula of V = 0.52*L*W2 and compared between
groups of mice by box-plot analysis. The mice
were housed and maintained in specific pathogen-free conditions in facilities approved by the
American Association for Accreditation of
Laboratory Animal Care and in accordance with
current regulations and standards of the United
States Department of Agriculture, United
States Department of Health and Human
Services, and the National Institute of Health.
Animal care and use was approved by the
Institutional Animal Care and Use Committee.
Human care of the mice was thoroughly
considered.
Statistical analysis
All the data was summarized and presented as
mean +/- the standard deviation (SD) with a
minimum of three observations per group.
Unpaired, paired or single sample Student’s
t-test with the Bonferroni correction for the multiple comparisons or Qi-Square test was applied
as appropriate. Significance was determined by
the alpha level of 0.05.
Results
KLF8 induces EMT-associated mammary stem
cell traits in MCF-10A cells
Our previous findings showed that stable
expression of KLF8 could induce EMT in breast
epithelial cells [9]. An intriguing recent finding is
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that breast epithelial cells gain the properties
of stem cells during EMT [4, 5]. To determine
whether during KLF8-induced EMT, the cells
obtain the properties of stem cells, we used our
recently generated MCF-10A cell line that
expresses tetracycline-regulated inducible
expression of KLF8 (10A-iK8) [15]. Effective
induction of EMT by the induced expression of
KLF8 in the cells, using TGF-b-induced MET in
the parental MCF-10A cells as a positive control, was verified by analysis of the changes in
the cell morphology and expression switch
between epithelial markers and mesenchymal
markers proteins (data now shown). Changes in
the human mammary stem cell surface markers CD44high/CD24low were first examined by
flow cytometry. We found that more than 90%
of the cells acquired a CD44high/CD24low expression pattern when the expression of KLF8 was
induced (10A-iK8/I) compared to only 33% of
the uninduced cells (10A-iK8/U) (Figure 1A and
1B). To verify this result, an independent human
mammary stem cell marker aldehyde dehydrogenase (ALDH) was analyzed. We found that
KLF8-expressing cells (10A-iK8/I) gained 3
times more ALDH-positive cells (5.76%) than
the cells not expressing KLF8 (10A-iK8/U) did
(1.34%) (Figure 1C and 1D). Similar results
were obtained in the cells treated with TGF-β
(Figures 1A, 1B and 2). Taken together, these
results clearly demonstrated that like TGF-β,
KLF8 could induce the mammary stem cell
traits via EMT.
KLF8-upregulated expression of miR-146a is
responsible for the induction of stem cell traits
in MCF-10A cells
MiRs have been implicated in the regulation of
both EMT and stem cells [40-43]. We sought to
examine the change in the expression profile of
miRs to identify target miRs of KLF8 responsible for the stem cell trait induction during EMT.
Among the 14 miRs whose levels were changed
≥ 10 times by the induction of KLF8 expression
(Figure 2), four were similarly regulated by
TGF-β treatment (Figure 3A). Among these 4
miRs, the miR-146a was the most significantly
upregulated in the invasive breast cancer cells
(MDA-MB-231, Hs578T and BT-549), but not in
the non-invasive breast cancer cells (MCF-7
and T47-D) (Figure 3B and 3C). Given that the
invasive and non-invasive cells represent the
mesenchymal and epithelial phenotypes,
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Figure 1. KLF8 induces stem cell traits in MCF-10A cells associated with EMT. A and B: Induction of an increase in
CD44high/CD24low cells by KLF8 and TGF-β. The 10A-iK8 cells were grown under uninduced (U) or induced (I) conditions, or the parental MCF-10A cells were grown untreated (-TGF-β) or treated (+TGF-β) with recombinant TGF-β (2.5
ng/ml) for two weeks. The cells were then prepared for FACS analysis of expression of the cell-surface markers
CD44 and CD24 as described in the Materials and Methods to identify CD44high/CD24low cell population (% shown
in red). C and D: Induction of an increase in ALDH+ cells by KLF8 and TGF-β. The 10A-iK8 cells or parental MCF-10A
cells were grown and treated as described above, followed by FACS analysis of ALDH expression in the cells using
the ALDEFLIOR assay as described in the Materials and Methods to identify the ALDH+ cell population. Representative FACS results are shown C where percentage of ALDH+ cell populations are indicated in red in the absence of
DEAB, normalized to those in the presence of DEAB. Fold changes in the ALDH+ cell populations caused by KLF8
expression or TGF-β treatment was summarized in D. *P < 0.01 compared to the uninduced or untreated cells.
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Figure 2. MicroRNA profile in 10A-iK8 cells. A: The
whole genomic miR PCR array (consisting of 4 consecutive sets) was screened for KLF8-regulated miRs in
the 10A-iK8 induced cells compared to the uninduced
cells. Assay and analysis were described in the Materials and Methods. B: Shown are miRs whose expression levels were increased or decreased by > 10 times
in the induced cells compared to the uninduced cells.

respectively, during EMT and KLF8 is aberrantly
overexpressed in these invasive cancer cells
[17], we decided to focus firstly on the miR146a for the subsequent experiments.
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To test if the upregulation of miR-146a is
required for the induction of stem cell traits by
KLF8, we blocked the function of miR-146a in
the 10A-iK8 cells. We found that when the cells
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Figure 3. MiR-146a is upregulated by KLF8 and TGF-β in MCF-10A cells and is highly overexpressed in invasive
breast cancer cells. A: Expression of the 14 miRs shown in Figure 2 was further compared between TGF-β treated
and untreated MCF-10A cells to identify target miRs (Hsa-mir-146a, -219-2-3p, -508-3p, and -513a-5p) common
to KLF8 and TGF-β. The expression of these 4 miRs was then examined in the indicated human breast cancer cell
lines. B: MiR-146a fold difference from that in the MCF-10A cells. C: The expression of MiR-146a was compared
between the cancer cells.

were treated with the miR-146a inhibitor, the
numbers of both ALDH positive cells and mammospheres were reduced by approximately
50% regardless of the induction of KLF8
expression (Figure 4A and 4B). This result suggested that miR-146a plays a mediating role
downstream of KLF8 for the induction of the
stem cell traits in the cells.
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To determine if overexpression of miR-146a
alone is sufficient to induce the stem cell traits,
we overexpressed miR-146a in the parental
MCF-10A cells. We found that the cells contained more than 2 times of ALDH positive cells
and mammosphere forming capability compared to the mock control cells (Figure 4C and
4D). This result suggested that the miR-146a
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Figure 4. KLF8 upregulated expression of miR-146a is responsible for the induction of stem cell traits in MCF-10A
cells. A and B: Inhibition of miR-146a suppresses the KLF8-dependent expression of ALDH and mammosphere formation. The 10A-iK8 cells were transfected with a Cy3 dye-labeled miR-146a inhibitor or an inhibitor control. After
3 days, the expression of KLF8 was induced in the cells and the cells were cultured for 7-10 days either in regular
culture plates for analysis of ALDH+ population (% shown in red) by FACS in the absence or presence of the ALDH
inhibitor DEAB (A) or in mammosphere culture dishes for mammosphere formation (B). Representative FACS results
and mammosphere images were shown in the left panels. C and D: Overexpression of miR-146a is sufficient to induce stem cell traits in MCF-10A cells. MCF-10A cells were infected with retroviral viruses expressing pre-miR-146a
or pre-miR control and selected with G418. The cells were then used for analysis of ALDH+ population (% shown in
red) by FACS (C) and mammosphere formation (D) similarly as described in A and B. The data represent the mean
± S.E. of at least three independent experiments in triplicate. *P < 0.05.
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Figure 5. MiR-146a-mediated induction of stem cell traits by KLF8 is correlated with drug resistance. A-C: Constitutive blocking of miR-146a function inhibits the induction of stem cell traits by KLF8. Retroviral viruses expressing the
miR-146a sponge (A) were used to infect the 10A-iK8 cells. After selected with puromycin, the 10A-iK8-146a-sponge
and mock-sponge control cells were cultured under uninduced (U) or induced (I) conditions for 7-10 days prior to
ALDH expression based FACS analysis (B) and mammosphere formation (C). *P < 0.05 compared to I-Mock group.
D: KLF8 induces the drug resistance in a miR-146a-dependeant manner. The 10A-iK8-sponge and mock control
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cells were grown under uninduced (U) or induced (I) conditions for 6 days. The cells were then treated with paclitaxel
(10 nM) for another 6 days. At the indicated time points, the cell viability was examined using the Promega CellTiterGlo® Luminescent Cell Viability Assay. Relative viability was normalized to the mock control cells (I-Mock) a day after
treatment was started. *P < 0.05 compared to I-Mock group at the same time points. The data represent the mean
± S.E. of at least three independent experiments in triplicate.

plays a critical role in inducing stem cell traits in
the cells.
MiR-146a-mediated induction of the stem cell
traits by KLF8 is correlated with drug resistance
Drug resistance is one of the hallmarks for
stem cells. To test if KLF8 grants the 10A-iK8
cells with the capability of resisting the cell killing effect of therapeutic drugs and whether
miR-146a plays such a role downstream of
KLF8 in the cells, we first generated the
10A-iK8-sponge cell line where miR-146a was
constitutively blocked by its inhibiting sponge
(10A-iK8-146a-sponge) and a sponge mock
control cell line (10A-iK8-mock-sponge). After
the inhibition of the stem cell traits under the
induced conditions by the miR-146a sponge
but not the mock sponge was confirmed (Figure
5B and 5C), the response of the cells to the killing effect of paclitaxel was determined. We
found that ~90% of the uninduced cells were
killed after treated for 6 days regardless of the
expression of the miR-146a-sponge or mocksponge (Figure 5D, columns 3 and 4, compare
days 6 to 1). In sharp contrast, induction of
KLF8 expression kept ~80% of the mocksponge cells viable (Figure 5D, columns 1, compare days 6 to 1). However, only ~30% of the
miR-146a-sponge cells survived the drug treatment regardless of the KLF8 expression (Figure
5D, columns 2, compare days 6 to 1). These
results strongly suggested that KLF8-induced
miR-146a-dependent stem cell traits are a
major contribution to the resistance of the cells
to the cytotoxic effect of the drug.
MiR-146a mediates KLF8 induced stem cell
traits by inhibiting NUMB expression
Potential molecular targets of miR-146a were
predicted by using several software programs
including TargetScan 5.1, miRanda, miRbase
and PITA. Among the potential targets, we
focused on NUMB given its well conserved
3’-UTR binding site for miR-146a and the inhibitory role in regulating Notch signaling, an important stem cell regulating pathway [44]. To test if
miR-146a directly targets NUMB transcript to
365

reduce its translation, we first performed NUMB
3’-UTR luciferase reporter analysis. We found
that the presence of the 3’-UTR caused approximately 40% reduction in the luciferase activity
when miR-146a was co-transfected (Figure 6B,
compare columns 2 to 1). The inhibitory effect
of miR-146a was lost when the miR-146a binding site in the 3’-UTR was disabled by mutagenesis (Figure 6B, compare columns 4 to 3). This
result suggested that NUMB is likely a specific
inhibitory target of the miR-146a in the cells. As
described above (Figure 3), miR-146a expression is differentially expressed between invasive and non-invasive breast cancer cells by
more than 100 times. To test if the miR-146a
expression is inversely correlated with the
expression of NUMB protein in the cancer cells,
we compared the NUMB protein expression
between the indicated invasive and non-invasive breast cancer cells by western blotting
(Figure 6C) followed by co-staining miR-146a
and NUMB protein in the cells (Figure 6D). The
western blotting results showed a highly inverse
correlation of expression between miR-146a
and NUMB protein in the cancer cells (Figures
3 and 4C). Similarly, the co-staining assay
showed that miR-146a was abundantly
expressed in the invasive Hs578T cells in which
there was only little expression of NUMB protein, whereas in the non-invasive T47D cells the
expression of NUMB was high and localized at
the cell-cell junctions where miR-146a was
absent (Figure 6D). Taken together, these data
suggested that miR-146a can be induced by
KLF8 and bind to NUMB 3’-UTR to suppress
NUMB expression in the invasive breast cancer
cells.
We then tested if overexpression of NUMB can
interfere with the induction of the stem cell
traits by KLF8. We infected the 10A-iK8 cells
with lentiviruses expressing a NUMB-GFP
fusion protein that does not contain the 3’-UTR
of NUMB. Lentivirus expressing only GFP was
used as a control. The cells were grown in mammosphere culture medium for 10 days in the
presence of KLF8 expression. We found that
the NUMB-GFP expressing cells formed 80%
Am J Cancer Res 2013;3(4):356-373
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Figure 6. MiR-146a targets the Notch signaling inhibitor NUMB. A and B: miR-146a binds the 3’-UTR of NUMB
transcript to inhibit NUMB translation. The miR-146a binding site in NUMB 3’-UTR was aligned with the miR-146a
sequence (A). The wild type (WT) NUMB 3’-UTR or its mutant defective in miR-146a binding (MUT) was cloned into
a luciferase reporter vector. The reporter plasmids were transfected into the MCF-10A cells stably expressing miR146a or miR control (described in Figure 4C and 4D) for luciferase activity analysis (B). *P < 0.05 compared to
column 1. C and D: NUMB expression is inversely correlated with miR-146a expression and invasiveness in breast
cancer cell lines. Whole cell lysates were used for anti-NUMB blotting with b-actin as a loading control (C). The expression of the endogenous miR-146a (green dots) and NUMB protein (red) in the indicated breast cancer cell lines
was determined by FISH-TSA as described in the Materials and Methods (D). The data represent the mean ± S.E. of
at least three independent experiments in triplicate.

less mammospheres compared to the GFP
expressing cells (Figure 7). This result suggested that KLF8 induces the stem cell traits by
inhibiting NUMB expression via likely the induction of the miR-146a expression.
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KLF8 potentiates oncogenic transformation of
MCF-10A cells
To test if KLF8 plays a role in transforming the
MCF-10A cells, we introduced the H-RasV12
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Figure 7. Overexpression of NUMB inhibits the induction of the stem cell traits by KLF8. 10A-iK8 cells expressing
NUMB-GFP or GFP control were generated as described in Materials and Methods. The NUMB cDNA did not contain
the 3’-UTR template. The cells were grown in stem cell culture plate under the induced conditions for 10 days to form
mammospheres. The mammospheres were imaged and counted. The data represent the mean ± S.E. of at least
three independent experiments in triplicate. *P < 0.05 compared to NUMB-group.

oncogene into the 10A-iK8 cells. The tumorigenecity of the cells were determined in nude
mice after mammary fat pad injection. By the
end of month 7, no detectable tumors were
formed by the parental MCF-10A cells or the
10A-iK8 cells regardless of the induction of
KLF8 expression (data not shown). In the
absence of KLF8 induction, the 10A-iK8RasV12 cells formed extremely small tumors of
< 5 mm3 (Figure 8A and 8B, U). In sharp contrast, when KLF8 expression in the cells was
induced, the tumors grew up to 1.3 cm3 with a
median size of approximately 0.5 cm3 (Figure
8A and 8B, I). This result suggested that KLF8
makes a critical contribution to the cell transformation presumably by inducing the stem cell
traits. To confirm the induced expression of
KLF8 and determine the expression pattern of
NUMB protein in the tumors, we performed IHC
co-staining experiments. We observed a high
level of NUMB protein expression in the
absence of KLF8 expression and a loss of
NUMB expression in the tumors that expressed
KLF8 (Figure 8C). Taken together, these results
support that inhibition of NUMB expression and
thus induction of stem cell traits by KLF8 (likely
via miR-146a) is an important mechanism
responsible for the cell transformation.
Discussion
Using immortalized human non-tumorigenic
mammary epithelial cells expressing inducible
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KLF8 or treated with TGF-β, a panel of human
breast cancer cell lines representing epithelial
or mesenchymal features, a combination of
multiple markers for mammary stem cells,
array screening and genetic modifications of
miRs in the cells, we demonstrate that the miR146a plays an important role in mediating the
induction and maintenance of breast CSCs during EMT potentially by repressing the expression of the Notch signaling inhibitor NUMB. This
finding provides new insights into the mechanisms for breast cancer progression and developing novel therapeutic strategies.
Our results are consistent with the recent
reports supporting cancer-promoting role of
miR-146a [45]. For example, in cisplatin-resistant MCF-7 lines that are characteristic of mesenchymal invasive cancer cell phenotype miR146a is the most highly upregulated among all
miRs compared to the cisplatin-sensitive,
parental epithelial non-invasive MCF-7 cells
[46]. MiR-146a was also found to be the most
highly upregulated miR in triple negative sporadic breast tumors and basal-like mammary
tumor epithelial cell lines and target the tumor
suppressor BRCA1 to promote proliferation
[47]. Evidence is also accumulating that supports a similar role of miR-146a in promoting
EMT, malignant transformation or therapeutic
resistance of various other types of cancer
including bronchial [48], gastric [49], liver [50],
thyroid [51], and pancreatic cancer [52], leuke-
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Figure 8. KLF8 potentiates Ras-induced transformation of MCF-10A cells. A and B: KLF8 enhances tumorigenecity
of MCF-10A cells induced by H-Ras-V12. The 10A-iK8-V12 cells were generated as described in Materials and Methods. Cells of 1 x 106 were injected into the fat pad of nude mice. The mice were fed with the Dox Diet to induce (I) the
expression of KLF8 in the tumor cells in vivo. Uninduced (U) KLF8 expression was maintained by feeding the mice
with the Control Diet not supplemented with doxycyclin. Tumors formed by the cells were monitored for 7 months
before the tumor images were taken (A) and tumor volumes were analyzed by box plot (B). P < 0.01 compared to
U group. C: Induction of KLF8 expression led to a decrease in NUMB expression in the tumors. Specimens of the
tumors from A & B were prepared for immunohistochemical staining of the expression of KLF8 and NUMB proteins.

mia [53, 54] and lymphoma [55, 56]. On the
other hand, some reports have indicated a
tumor-inhibiting role of miR146a [57-59]. It
remains to be answered whether this discrepancy was due to the difference in the experi-
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mental conditions, the stages of tumors or cancer types studied, or even an undiscovered
double-faced role of miR-146a in cancer.
Nevertheless, given that KLF8 supports tumor
progression of multiple cancer types [8], miR-
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146a may contribute to the role for KLF8 in
regulating the cancer types other than breast
cancer as well.
Several miR-146a regulators have recently
been reported including NF-κB [51, 53, 55, 56],
TGF-β [48] and breast cancer metastasis suppressor 1 [58]. On the other hand, transcripts
of several genes have been identified as miR146a targets such as NF-κB [57, 59], BRCA1
[47], and SMAD4 [49, 50, 54]. It will be interesting to determine if KLF8 activates miR-146a
promoter directly or indirectly by targeting
these or other miR-146a regulating genes and
whether other miR-146a target transcripts
besides NUMB [21] are also regulated by KLF8
via miR-146a in the regulation of EMT and/or
CSCs.
It should be noted that in addition to miR-146a,
several other KLF8-regulated miRs also
respond to EMT including miR-219-2-3p, miR508-3p, and miR-513a-5p (see Figure 3).
Interestingly, expression of some of these miRs
is highly altered in either invasive or non-invasive breast cancer cells, yet others are modestly underexpressed in both invasive and noninvasive breast cancer cells. These results suggest that these KLF8 target/effector miRs may
contribute differentially to the EMT-dependent
induction of breast stem cells responsible for
the development and growth of primary tumors,
the initiation of tumor invasion and metastasis,
the colonization and growth of the secondary
tumors at the metastatic sites, or throughout
the entire process of tumor progression.
Besides these four miRs, other potential KLF8
target miRs (see Figure 2) may also play important roles in EMT-associated CSC induction.
Studies have shown that miR-200 family and
associated miRs regulate EMT and play an
important role in tumor progression [60, 61].
These miRs are similarly regulated in the cells
expressing high levels of KLF8 (Figures 2 and
3), cisplatin-resistant mesenchymal breast
cancer cells [46], and invasive prostate cancer
cells [62]. Interestingly, miR-200 family miRs
and the ZEBs mutually down-regulate each
other, which has been shown to play an important role in EMT, CSCs and metastatic progression of cancer [60, 63-69]. These results indicate that KLF8 and ZEBs may cooperate in
regulating their common target miRs and also
suggest an interesting possibility of cross-talk
between KLF8 and ZEBs and potentially other
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EMT-regulating transcription factors through
the miRs-mediated feedback regulation [60].
Resistance to cancer therapies is a major hurdle of clinical intervention of cancer and one of
the hallmarks of CSCs [3]. Several recent studies have shown that miR-146a is an important
positive regulator of drug resistance [46, 50,
54]. The other potential KLF8-downregulated
miRs such as miR-200 family have been reported to inhibit resistance to therapeutic drugs
such as microtubule-interfering chemotherapeutic agents [70-72]. We have recently demonstrated that KLF8 promotes cell resistance
against the cytotoxic effects of DNA damaging
agents via PARP-1-dependent DNA damage
responses [23]. Interestingly, PARP-1 has been
reported to contribute to resistance of hepatocellular carcinoma CSCs against multiple therapeutic drug types [73]. These results suggest
that in addition to promoting tumorigenesis and
metastasis, KLF8 could also play a role in maintaining or enhancing therapeutic resistance of
CSCs by more than one mechanism and miRs
could play a role downstream of KLF8 in the
regulation of DNA damage responses. Lastly,
the cytotoxic resistance could be one of the
potential mechanisms provided by KLF8 that
help the H-RasV12 expressing cells form
tumors more easily and quickly. Experiments
are in progress to test these interesting
possibilities.
In summary, this report demonstrates a novel
mechanism of breast cancer progression by
which KLF8 induces CSCs to promote tumorigenesis and drug resistance. This finding provides new insights into developing novel therapeutic strategies to inhibit CSCs and sensitize
tumor cells to the otherwise ineffective conventional therapies.
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